Taira J, Yamaguchi M, Tashiro A, Kida A, Suzuki K, Sakai K, Matsumoto K, Aoki S.
Computer-Assisted Identification of Inhibitor with Novel Pharmacophore Targeting First Kringle Domain of Hepatocyte Growth Factor.
ChemistrySelect (2023) https://doi.org/10.1002/slct.202301577

 

Ryu Imamura, Hiroki Sato, Dominic Chih-Cheng Voon, Takayoshi Shirasaki, Masao Honda, Makoto Kurachi, Katsuya Sakai, Kunio Matsumoto

Met receptor is essential for MAVS-mediated antiviral innate immunity in epithelial cells independent of its kinase activity

Proc Natl Acad Sci U S A. e2307318120 (2023) https://www.pnas.org/doi/10.1073/pnas.2307318120

 

Naoya Kawakami, Hiroki Sato, Naohiro Terasaka, Kunio Matsumoto, Hiroaki Suga.

MET-Activating Ubiquitin Multimers.

Angew Chem Int Ed Engl. e202307157. (2023)  https://onlinelibrary.wiley.com/doi/10.1002/anie.202307157

 

Shota Warashina, Hiroki Sato, Maki Zouda, Maiko Takahashi, Yasuhiro Wada, Toby Passioura, Hiroaki Suga, Yasuyoshi Watanabe, Kunio Matsumoto, Hidefumi Mukai.

Two-Chain Mature Hepatocyte Growth Factor-Specific Positron Emission Tomography Imaging in Tumors Using 64Cu-Labeled HiP-8, a Nonstandard Macrocyclic Peptide Probe.

Mol Pharm. Mar 2. (2023) https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.2c01020

 

Sakai K, Sugano-Nakamura N, Mihara E, Rojas-Chaverra NM, Watanabe S, Sato H, Imamura R, Voon DCC, Sakai I, Yamasaki C, Tateno C, Shibata M, Suga H, Takagi J, Matsumoto K.

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions.

Nat Biomed Eng, (2022), https://doi.org/10.1038/s41551-022-00955-6

 

Hino N, Matsuda K, Jikko Y, Maryu G, Sakai K, Imamura R, Tsukiji S, Aoki K, Terai K, Hirashima T, Trepat X, Matsuda M.

A feedback loop between lamellipodial extension and HGF-ERK signaling specifies leader cells during collective cell migration. 

Dev Cell, 57, 2290-2304, (2022), https://doi.org/10.1016/j.devcel.2022.09.003

 

Shirasaki T, Yamagoe S, Shimakami T, Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M.

Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.

Nat Commun. 13(1):3176. https://doi.org/10.1038/s41467-022-30879-3, 2022

 

Puppulin L, Kanayama D, Terasaka, N, Sakai K, Kodera N, Umeda K, Sumino A, Marchesi A, Weilin W, Tanaka Hideo,

Fukuma T, Suga H, Matsumoto K, Shibata, M.

Macrocyclic Peptide-Conjugated Tip for Fast and Selective Molecular Recognition Imaging by High-Speed Atomic Force Microscopy.

ACS Appl. Mater. Interfaces, https://doi.org/10.1021/acsami.1c17708, 2021

 

Komatsu Y. Terasaka N, Sakai K, Mihara E, Wakabayashi R, Matsumoto K, Hilvert D, Suga H.

De novo peptide grafting to a self-assembling nanocapsule yields a hepatocyte growth factor receptor agonist.

iScience, https://doi.org/10.1016/j.isci.2021.103302, 2021.

 

Tahira Y, Sakai K, Sato H, Imamura R, Matsumoto K.

Dimer interface in natural variant NK1 is dispensable for HGF-dependent Met receptor activation. 

Int J Mol Sci, 22, 9240, 2021

 

Kajiwara K, Yamano S, Aoki K, Okuzaki D, Matsumoto K, Okada M.

CDCP1 promotes compensatory renal growth 1 by integrating Src and Met signaling. 

Life Science Alliance, 4: e202000832, 2021.

 

Mihara E, Watanabe S, Bashiruddin NK, Nakamura N, Matoba K, Yumi Sano, Maini R, Yin Y, Sakai K, Arimori T,

Matsumoto K, Suga H, Takagi J.

Lasso-grafting of macrocyclic peptide pharmacophores yields multi-functional proteins. 

Nat Commun, 12: 1543, 2021.

 

Sakai K, Nishiuchi T, Tange S, Suzuki Y, Yano S, Terashima M, Suzuki T, Matsumoto K. Proteasomal degradation of

polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion. Sci Rep, 10: 16678, 2020.

 

Sato H, Suga H, Matsumoto K, Sakai K. Cyclic peptide-based biologics regulating HGF-MET. Int J Mol Sci, 21: 7977,

2020.

 

Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A,

Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat Commun, 11: 4607, 2020.

 

Umitsu M, Sakai K, Tamura-Kawakami K, Matsumoto K, Takagi J. The constitutive high affinity Met binding site in

the kringle domain is dispensable for the signaling activity of hepatocyte growth factor. J Biochem, 167: 577-586, 2020.

 

Mizutani S, Matsumoto K, Kato Y, Mizutani E, Mizutan H, Shibata K. New insights into human endometrial

aminopeptidases in both implantation and menstruation. Biochim Biophys Acta – Proteins & Proteomics, 1868: 140332, 2020.

Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, Takagi J, Kato Y, Mukai H, Warashina S, Zouda M,

Watanabe Y, Yano S, Shibata M, Suga H, Matsumoto K. Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. Nat Chem Biol, 15: 598-606, 2019.

 

Jangphattananont N, Sato H, Imamura R, Sakai K, Terakado Y, Murakami K, Barker N, Oshima H, Oshima M, Takagi J,

Kato Y, Yano S, Matsumoto K. Distinct localization of mature HGF from its precursor form in developing and repairing stomach. Int J Mol Sci, 20: 2944, 2019.

 

Miao W, Sakai K, Sato H, Imamura R, Jangphattananont N, Takagi J, Nishita M, Minami Y, Matsumoto K. Impaired

ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer. Cancer Sci, 110: 3340-3349, 2019.

Miao W, Sakai K, Ozawa N, Nishiuchi T, Suzuki Y, Ito K, Morioka T, Umitsu M, Takagi J, Suga H, Matsumoto K. Cellular

signaling and gene expression profiles evoked by a bivalent macrocyclic peptide that serves as an artificial MET receptor agonist. Sci Rep, 8: 16492, 2018.

 

Miao W, Sakai K, Imamura R, Ito K, Suga H, Sakuma T, Yamamoto T, Matsumoto K. MET activation by a macrocyclic

peptide agonist couples to biological responses differently from HGF in a context-dependent manner. Int J Mol Sci, 19: 3141, 2018.

Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP.

Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 108: 296-307, 2017.

 

Imamura R, Matsumoto K. Hepatocyte growth factor in physiology and infectious diseases.

Cytokine, 98: 97-106, 2017.

 

Sato H, Aoki S, Kato T, Matsumoto K. Hepatocyte growth factor. Encyclopedia of Signaling Molecules, 2nd edition,

pp.2352-2364, Springer, 2017.

 

Jahangiri A, Nguyen A, Chandra A, Sidorov M, Yagnik G, Rick J, Han S, Chen W, Flanigan P, Schneidman-Duhovny D,

Mascharak S, De Lay M, Imber B, Park C, Matsumoto K, Lu K, Bergers G, Sali A, Weiss W, Aghi MK. A cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci USA, 114: E8685-E8694, 2017.

 

Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T,

Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M. Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. Cancer Sci, 108: 1263-1270, 2017.

 

De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP. Targeting the hepatocyte growth factor/Met

pathway in cancer. Biochem Soc Trans, 45: 855-870, 2017.g cancer. Cancer Sci, 108: 1263-1270, 2017.

 

 

Adachi E, Sakai K, Nishiuchi T, Imamura R, Sato H, Matsumoto K.

Cell-autonomous changes in Met receptor expression regulate the growth and metastatic characteristics in malignant melanoma. Oncotarget, 7: 70779-70793.

 

Umitsu M, Sakai K, Ogasawara S, Kaneko M, Asaki R, Tamura-Kawakami K, Kato Y, Matsumoto K, Takagi J.

Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies. Sci Rep, 6: 33149, 2016

 

Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K,

 Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib kinases. Cancer Res, 76: 1506-1516, 2016.

Ito K ’, Sakai K ’ , Suzuki Y, Ozawa N, Hatta T, Natsume T, Matsumoto K , Suga H . Artificial human Met

agonists based on macrocycle scaffolds. Nat Commun, 6: 6373, 2015. ( ’equal contribution)

 

Sakai K, Aoki S, Matsumoto K. Hepatocyte growth factor and Met in drug discovery. J Biochem, 157:

271-284, 2015.

 

Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I,

Tatsumi K, Tagawa M. A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.SpringerPlus, 4: 358.

Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K, Matsumoto

K. Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant

human hepatocyte growth factor in rats with renal injury. Pharmacology, 94: 190-197, 2014.

 

Sakai K, Kinoshita T, Matsumoto K. Hepatocyte growth factor. In “Reference Module in Biomedical

Sciences”, pp. 436-442, Elsevier Inc., 2014.

 

Matsumoto K, Funakoshi H, Takahashi H, Sakai K. HGF-Met pathway in regeneration and drug

discovery. Biomedicines, 2: 275-300, 2014.

 

Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto

K, Matsumoto K, Yonekura K, Yano S. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol, 9: 775-783, 2014.

 

Tanimoto A, Yamada T, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Receptor ligand-triggered

resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.Oncotarget,5: 4920-4928, 2014.

 

Oyanagi J, Kojima N, Higashi S, Kikuchi K, Sakai K, Matsumoto K, Miyazaki K. Inhibitor of

transforming growth factor-β potentiates fibroblast-dependent tumor cell invasion into collagen matrix by increasing secretion of hepatocyte growth factor from fibroblasts. Exp Cell Res, 326:267-279, 2014.

 Nakayama M, Sakai K, Yamashita A, Nakamura T, Suzuki Y, Matsumoto K. Met/HGF receptor

activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes. Cytokine, 62:446-452, 2013.

 

Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K. α-Lipoic acid-induced

inhibition of proliferation and Met phosphorylation in human non-small cell lung cancer cells.Cancer Lett,335: 472-478, 2013.

 

Xu Q, Sakai K, Nakayama M, Suzuki Y, Tambo C, Sakai Y, Matsumoto K. Suppression of fibrogenic

gene expression and liver fibrosis using a synthetic prostacyclin agonist. Biomed Res, 34: 241-250,2013.

 

Sugiura T, Takahashi S, Sano K, Abe T, Fukuta K, Adachi K, Nakamura T, Matsumoto K, NakamichiN,

Kato Y. Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans. J Pharm Sci, 102, 237–249, 2013

 

Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A, Komatsu S,

Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Kokuba Y, Nakamura T, Matsumoto K,Otsuji E. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt,MAPK and STAT3, in CT26 murine cells. Int J Oncol, 42: 535-542, 2013.

 

Hirata Y, Kurobe H, Uematsu E, Yagi S, Soeki T, Yamada H, Fukuda D, Shimabukuro M, Nakayama M,

Matsumoto K, Sakai Y, Kitagawa T, Sata M. Beneficial effect of a synthetic prostacyclin agonist,ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol, 699: 81-87, 2013. doi:10.1016/j.ejphar.2012.11.045.

 

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. The

novel PI3K-mTOR inhibitor, BEZ235, circumvents erlotinib- resistance of EGFR mutant lung cancer cells triggered by HGF. Int J Cancer, 133: 505-513, 2013.

 

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto

K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8: e62104,2013.

 

Kubota T, Matsumura A, Taiyoh H, Izumiya Y, Fujiwara H, Okamoto K, Ichikawa D, Shiozaki A,

Komatsu S, Nakanishi M, Kuriu Y, Murayama Y, Ikoma H, Ochiai T, Nakamura T, Matsumoto K,Nakamura T, Otsuji E. Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells. Oncol Rep, 30: 567-572, 2013.

 

Nakamura A, Nagaya N, Obata H, Sakai K, Sakai Y, Yoshikawa M, Hamada K, Matsumoto K, Kimura

H. Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. Circulation J, 77: 2127-2133, 2013.

 

Tsunemi S, Iwasaki T, Kitano S, Matsumoto K, Takagi-Kimura M, Kubo S, Tamaoki T, Sano H.

Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis. Arthritis Res Ther, 15: R75, 2013.

 

Hayakawa H, Ichihara E, Ninomiya T, Takata S, Ohashi K, Masayuki Yasugi, Sakai K, Matsumoto K,

Takigawa N, Tanimoto M, Kiura K. Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in EGFR mutated lung cancer model. Cancer Sci, 104: 1440-1446,2013.

 

Uchida T, Hazekawa M, Yoshida M, Matsumoto K, Sakai Y. A novel long-acting prostacyclin agonist

(ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP receptor signaling. J Pharmacol Sci, 123: 392-401,2013.

 

Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K,

Yoshie O, Yano S. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Sci, 104: 1640-1646, 2013.

 

Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H,Yasumoto K, Matsumoto K, Yano S. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One, 8: e84700,2013.

 

 

 

 

Xu Q, Nakayama M, Suzuki Y, Sakai K, Nakamura T, Sakai Y, Matsumoto K. Suppression of acute

hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression. Am J Physiol., 302: G420-G429, 2012.

 

Suzuki Y, Yamamoto K, Ando J, Matsumoto K, Matsuda T. Arterial shear stress augments the

differentiation of endothelial progenitor cells adhered to VEGF-bound surfaces. Biochem Biophys Res Commun, 423: 91-97, 2012.

 

Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S. Hepatocyte growth factor

induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J ThoracicOncol, 7: 272-280, 2012.

 

Hirata Y, Shimabukuro M, Uematsu E, Soeki T, Yamada H, Sakai Y, Nakayama M, Matsumoto K,

Igarashi T, Sata M. A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity,ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol, 674: 352-358, 2012.

 

Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y,

Sone S, Uenaka T, Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.Clin Cancer Res, 18: 1663-1671, 2012.

 

Nasu T, Kinomura M, Tanabe K, Yamasaki H, Htay SL, Saito D, Hinamoto N, Watatani H, Ujike H,

Suzuki Y, Sugaya T, Sugiyama H, Sakai Y, Matsumoto K, Maeshima Y, Makino H. A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol-Renal Physiol, 302: F1616-F1629, 2012.

 

Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K,

Mitsudomi T, Yano S. Hsp90 inhibition overcomes HGF-triggrering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis. J Thoracic Oncol, 7: 1078-1085, 2012.

 

Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M,

Mano H, Uenaka T, Yano S. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res,18: 3592-3602, 2012.

 

Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Mukaida N,

Shimizu E, Nishioka Y, Sone S, Uenaka T, Yano S. Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. Am J Pathol,181: 1034-1043, 2012.

 

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, ita K, Nakamura T, Matsumoto K,

Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Combined therapy with mutant-selective EGFRinhibitor and Met kinase inhibitor to overcome erlotinib resistance in EGFR mutant lung cancer.Mol Cancer Ther, 11:2149-2157, 2012.

 

Yamabayashi C, Koya T, Kagamu H, Kawakami H, Kimura Y, urukawa T, Sakagami T, Hasegawa T,

Sakai Y, Matsumoto K, Nakayama M, Gelfand EW, Suzuki E, Narita I. A novel prostacyclin agonist

protects to airway hyperresponsiveness and remodeling in mice. Am J Respir Cell Mol Biol,47:170-177, 2012.

 

Goshima K, Nakase J, Xu Q, Matsumoto K, Tsuchiya H. Repair of segmental bone defects in rabbit tibia

using a complex of b-tricalcium phosphate and hepatocyte growth factor. J Orthopaedic Sci, 17:639-648, 2012.

 

 

  

Sakai K, Nakamura T, Suzuki Y, Imizu T, Matsumoto K. 3D collagen and MT1MMPdependent MMP2

activation in human malignant mesothelioma cells. Biochem Biophys Res Commun, 412: 98-103,2011.

 

Sakai, K., Nakamura, T., Suzuki Y, Matsumoto, K. Significance, mechanisms, and progress of anticancer

drugs targeting HGF-Met. In “Cancer Treatment”, InTech Open Access Publisher, pp. 313-332,2011.

 

Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much

more than a growth factor. J Gastroenterol Hepatol, 26: 188-202, 2011.

 

Sakai K, Nakamura T, Kinoshita T, Nakamura T, Matsumoto K. HGF-antagonists: structure, activities,

and anti-cancer approach. Current Signal Transduction Therapy, 6: 191-199, 2011.

 

Komamura K, Tatsumi R, Tsujita-Kuroda Y, Onoe T, Matsumoto K, Nakamura T, Miyazaki J, Horio T,

Sugimachi M. Cellular injury of cardiomyocytes during hepatocyte growth factor gene transfection with ultrasound-triggered bubble liposome destruction. J Drug Delivery, 2011: 1-8, 2011.

 

Azuma H, Isaka Y, Nomi H, Inamoto T, Li XK, Hőunig T, Takabatake Y, Ichimaru N, Ibuki N,

Matsumoto K, Ubai T, Katsuoka Y, Takahara S. Induction of donor-specific tolerance using superagonistic CD28 antibody in rat renal allografts: Regulatory T-cell expansion before engraftment may be important. Transplantation, 90: 1328-1335, 2011.

 

Mizuno S, Ikebuchi F, Fukuta K, Kato T, Matsumoto K, Adachi K, Nakamura T. Recombinant human

HGF, but not rat HGF, elicits glomerular injury and albuminuria in normal rats via an immune complex-dependent mechanism. Clin Exp Pharmacol Physiol., 38: 192-201, 2011.

 

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-

TKIs in EGFR mutant lung cancer. Clin Cancer Res., 17: 2260-2269, 2011.

 

Yasui T, Ohuchida K, Zhao M, Cui L, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K,

Matsumoto K, Tanaka M. Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells. Anticancer Res., 31(4): 1279-1287, 2011.

 

Taiyoh H, Kubota T, Fujiwara H, Matsumura A, Murayama Y, Okamoto K, Ichikawa D, Ochiai T,

Nakamura T, Matsumoto K, Nakamura T, Otsuji E. NK4 gene expression enhances 5-fluorouracil-induced apoptosis of murine colon cancer cells. Anticancer Res., 31: 2217-2224, 2011.

 

Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S,

Itoi K, Utsugi T, Yasumoto K, Yano S. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol, 179: 1483-1493, 2011.

 

Ueshima K, Kitaoka K, Nakase J, Xu Q, Matsumoto K, Tsuchiya H. Promotion of rabbit ligament healing

by local delivery of hepatocyte growth factor. J Orthopaedic Sci, 16: 451-457, 2011.

 

Hirata Y, Soeki T, Yamada H, Shiota A, Shimabukuro M, Sakai Y, Nakayama M, Matsumoto K, Igarashi

T, Sata M. A synthetic prostacyclin agonist, ONO-1301, ameliorates ventricular remodeling after acute myocardial infarction via upregulation of HGF in rat. Biomed Aging Pathol, 1:90-96, 2011.

  

 

Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K. Inhibition of

Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in

malignant pleural mesothelioma. Int J Cancer, 127: 1948-1957, 2010.

 

Sakai K, Oka K, Matsumoto K, Nakamura T. p27 Nuclear localization and growth arrest caused by

perlecan knockdown in human endothelial cells. Biochem Biophys Res Commun, 392: 403-408,2010.

 

Nakamura T, Sakai K, Nakamura T, Matsumoto K. Anti-cancer approach with NK4: Bivalent action and

mechanisms. Anti-Cancer Agent Med Chem, 10: 36-46, 2010.

 

Nakase J, Kitaoka K, Matsumoto K, Tomita K. Facilitated tendon-bone healing by local delivery of

recombinant hepatocyte growth factor in rabbits. Arthroscopy, 26: 84-90, 2010.

 

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Hepatocyte growth

factor reduces susceptibility to an irreversible epigdermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res, 16: 174-183, 2010.

 

Onimaru M, Ohuchida K, Mizumoto K, Nagai E, Cui L, Toma H, Takayama K, Matsumoto K,

Hashizume M, Tanaka M. hTERT-promotrt- dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci, 101: 735-742, 2010.

 

Onimaru M, Ohuchida K, Egami T, Mizumoto K, Nagai E, Cui L, Toma H, Matsumoto K, Hashizume M,

Tanaka M. Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells. Cancer Gene Ther, 17: 541-549, 2010.

Sakai K, Nakamura T, Matsumoto K, Nakamura T. Angioinhibitory Action of NK4 Involves Impaired

Extracellular Assembly of Fibronectin Mediated by Perlecan-NK4 Association. J. Biol. Chem.,284: 22491-22499, 2009.

 

Kadoyama K, Funakoshi H, Ohya-Shimada W, Nakamura T, Matsumoto K, Matsuyama S, Nakamura T.

Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS. Neurosci. Res., 65:194-200, 2009.

 

Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, Hoshii T, Ohmura M, Ooshio T, Nakada M,

Sawamoto K, Matsumoto K, Oshima M, Asano M, Saya H, Okano H, Suda T, Hamada J, Hirao A.Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci USA, 106: 17163-17168, 2009.

 

Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K, Nakamura T.

Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci., 100: 1351-1358, 2009.

 

Fukuta K, Adachi E, Matsumoto K, Nakamura T. Different reactivities of enzyme-linked immunosorbent

assays for hepatocyte growth factor. Clinica Chimica Acta, 402: 42-46, 2009.

 

Kamimoto M, Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor prevents multiple organ

injuries in endotoxemic mice through a heme oxygenase-1- dependent mechanism. Biochem Biophys Res Commun, 380: 333-337, 2009.

 

Liu KX, Kato Y, Matsumoto K, Nakamura T, Kaku T, Sugiyama Y. Characterization of the enhancing

effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes.Pharm Res,26: 1012-1021, 2009.

 

Egami T, Ohuchida K, Miyoshi K, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M.

Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer. Cancer Sci, 100:722-729, 2009.

 

Kubota T, Fujiwara H, Matsumura A, Taiyoh H, Ichikawa I, Okamoto K, Matsumoto M, Nakamura T,

Otsuji E. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis, 26: 447-456, 2009.

 

Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, Nakamura,T. Tryptophan

2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol. Brain, 2: 8, 2009.

 

Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto O, Fujiwara H, Ikoma H,

Nakanishi N, Kikuchi S, Ochiai T, Sakakura C, Kokuba Y, Suzuki Y, Matsumoto K, Nakamura T,Otsuji E. Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T-lymphocyte activation. Int J Cancer, 125: 2879-2886, 2009.

 

Egami T, Ohuchida K, Yasui T, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M.

Up-regulation of integrin-b3 in radioresistant pancreatic cancer impairs adenovirus-mediated gene therapy. Cancer Sci. 100: 1902-1907, 2009.

 

Wang W, Li Q, Matsumoto K, Kayano Y, Matsumoto I, Oda M, Watanabe G, Nishioka Y, Sone S, Yano

S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Clin. Cancer Res., 15(21): 6630-6638, 2009.

 

 

 

Hayata D, Fukuta K, Matsumoto K, Adachi E, Hanada K, Adachi K, Nakamura T. Generation of

engineered recombinant hepatocyte growth factor cleaved and activated by Genenase I. J Biotechnol, 133: 478-485, 2008.

 

Matsumoto K, Nakamura T, Sakai K, Nakamura, T. Hepatocyte growth factor and Met in tumor biology

and therapeutic approach with NK4. Proteomics, 8: 3360-3370, 2008.

 

Nakamura T, Nakamura T, Matsumoto K. The functions and possible significance of Kremen as the

gatekeeper of Wnt signaling in development and pathology. J Cell Mol Med, 12: 391-408, 2008.

 

Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci, 13:

1943-1951, 2008.

 

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M,

Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with EGF Receptor activating mutations.Cancer Res, 68: 9479-9487, 2008.

 

Ito W, Tanimoto M, Ono K, Mizuno S, Yoshida A, Koga H, Fuchimoto Y, Kondo N, Tanimoto Y, Kiura

K, Matsumoto K, Kataoka M, Nakamura T, Gelfand E, Kanehiro A. Growth factors temporally

associate with airway responsiveness and inflammation in allergen-exposed mice. Int Arch Allergy Immunol, 145: 324-339, 2008.

 

Kiyama S, Yamada T, Iwata H, Sekino T, Matsuo H, Yoshida N, Miyahara T, Umeda Y, Matsuno Y,

Kimura M, Matsumoto K, Nakamura T, Takemura H. Reduction of fibrosis in a rat model of non-alcoholic steatohepatitis cirrhosis by human HGF gene transfection using electroporation. J Gastroenterol Hepatol,23: e471-476, 2008.

 

Akita H, Takagi N, Ishihara N, Takagi K, Murotomi K, Funakoshi H, Matsumoto K, Nakamura T, Takeo

S. Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excitotoxic injury in cultured hippocampal neurons. Exp Neurol, 210: 83-94, 2008.

 

Suzuki Y, Funakoshi H, Machide M, Matsumoto K, Nakamura T. Regulation of cell migration and

cytokine production by HGF-like protein (HLP)/macrophage stimulating protein (MSP) in primary microglia. Biomed Res, 29: 77-84, 2008.

 

Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura

T, Tanaka M. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin. Cancer Res, 14: 1859-1867,2008. Biomed Res, 29: 77-84, 2008.

 

 

Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Inhibition of colon cancer growth and

metastasis by NK4 gene repetitive delivery in mice. Biochem Biophys Res Commun, 358: 117-123,

2007.

 

Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. In “Gene Therapy

2007” (eds, Ochiai T, Shimada H, Tagawa M), pp. 22-33, Medical View Co., 2007.

 

Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, Matsumoto K, Nakamura T,

Nukiwa T, Saijo Y. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther, 14: 894-903, 2007.

 

Choi YL, Tsukasaki K, O'neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y,

Tsutsumi S, Kaneda R, Takada S, Aburatani H, Kamihira S, Nakamura T, Tomonaga M, Mano H. A genomic analysis of adult T-cell leukemia. Oncogene, 26: 1245-1255, 2007.

 

Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T,

Ikeda Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells in vivo; molecular targeting of angiogenic growth factor. Blood, 109: 3042-3049,2007. 

 

Sakiyama R, Fukuta K, Matsumoto K, Furukawa M, Takahashi Y, Nakamura T. Stimulation of

Hepatocyte Growth Factor Production by Heparin-derived Oligosaccharides. J Biochem, 141: 653-660, 2007.

 

Nakano M, Takagi N, Takagi K, Funakoshi H, Matsumoto K, Nakamura T, Takeo S. Hepatocyte growth

factor promotes the number of PSD-95 clusters in young hippocampal neurons. Exp Neurol, 207:195-202, 2007.

 

Makiuchi A, Yamaura K, Mizuno S, Matsumoto K, Nakamura T, Amano J, Ito K. Hepatocyte growth

factor prevents pulmonary ischemia-reperfusion injury in mice. J Heart Lung Transplant. 26: 935-943, 2007.